HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

2,5-dichloro-4-bromophenol (B 2)

Subscribe to New Research on 2,5-dichloro-4-bromophenol

RN given refers to parent cpd

Also Known As:

B 2; 2,5-dichloro-4-bromophenol, calcium salt; 2,5-dichloro-4-bromophenol, diethanolamine salt; 2,5-dichloro-4-bromophenol, monoethanolamine salt; 2,5-dichloro-4-bromophenol, potassium salt; 2,5-dichloro-4-bromophenol, sodium salt; phebrol; sodium 2,5-dichloro-4-bromophenol; 4-bromo-2,5-dichlorophenol

Networked: 699 relevant articles (23 outcomes, 64 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 58
- Hydrocarbons: 412
  - Cyclic Hydrocarbons: 3
    - Aromatic Hydrocarbons: 132
      - Benzene Derivatives: 13
        Chlorobenzenes: 4
        Chlorophenols: 58
        2,5-dichloro-4-bromophenol: 699
- Phenols: 309
  - Chlorophenols: 58
    - 2,5-dichloro-4-bromophenol: 699

Experts

1.	Couture, Réjean: 9 articles (01/2012 - 04/2002)
2.	Calixto, J B: 8 articles (01/2013 - 10/2001)
3.	Bader, Michael: 8 articles (10/2011 - 12/2002)
4.	Calixto, João B: 6 articles (12/2012 - 12/2002)
5.	Ongali, Brice: 6 articles (12/2005 - 04/2002)
6.	Parton, Roger: 5 articles (06/2012 - 07/2002)
7.	Scharfstein, Julio: 5 articles (03/2012 - 11/2006)
8.	Ferreira, J: 5 articles (05/2008 - 10/2001)
9.	Zamri-Saad, M: 4 articles (11/2015 - 10/2006)
10.	Campos, M M: 4 articles (08/2013 - 10/2001)

Related Diseases

1.	Pain (Aches) 04/01/2014 - "Pain intensity was measured on a 100-mm non-graduated visual analogue scale (VAS), and it was significantly greater in group A (8 mm) than that in group B (2 mm). " 01/01/1991 - "Comparing the percentage of dysmenorrhoea it emerges: 1) that dysmenorrhoea is present in a lower percentage in subjects in Group A (68.19%) in respect to women in Group B; 2) that in a considerable number of girls in Group B it was observed that there was a regression or an improvement in the pain symptomatology after the beginning in athletic activity; 3) dysmenorrhoea was much less in the more intense the sports activity (Groups C and D). " 10/01/2011 - "[Twenty-one cases of pain caused by earthquake treated mainly with acupuncture at Jiaji (EX-B 2)]." 10/19/2001 - "This review summarizes the most recent data from various animal models which convey support for a role of B(2) receptors in the acute phase of the inflammatory and pain response, and for a role of B(1) receptors in the chronic phase of the response. " 10/01/2001 - "The gathering of results has demonstrated that both B(1) and B(2) receptors seem to exert a meaningful role during nociceptive responses, the B(1) receptor being most relevant in the chronic stages of inflammatory pain. "
2.	Hemorrhagic Septicemia (Haemorrhagic Septicemia) 12/01/2007 - "Safety and protective efficacy of intramuscular vaccination with a live aroA derivative of Pasteurella multocida B:2 against experimental hemorrhagic septicemia in calves." 08/18/2012 - "The efficacy of an intranasal haemorrhagic septicaemia vaccine containing live gdhA derivative Pasteurella multocida B:2 was tested in buffaloes in Sabah. " 08/18/2012 - "Efficacy of intranasal vaccination of field buffaloes against haemorrhagic septicaemia with a live gdhA derivative Pasteurella multocida B:2." 01/01/2011 - "Efficacy of an inactivated recombinant vaccine encoding a fimbrial protein of Pasteurella multocida B:2 against hemorrhagic septicemia in goats." 03/01/2005 - "Efficacy of vaccination of calves against hemorrhagic septicemia with a live aroA derivative of Pasteurella multocida B:2 by two different routes of administration."
3.	Neoplasms (Cancer) 04/01/1991 - "Histopathologic evaluations revealed that a) SMC had no effect; b) 2- and 5-day T cells, injected at E:T ratios greater than 5:1, caused significant reduction in tumor size; and c) 2- or 5-day T cells, at a 40:1 E:T ratio, resulted in little or no histologic evidence of tumor. " 12/01/2015 - "In group B, 2 patients are alive with NED, 1 patient is alive with disease, and the remaining 12 patients have died a tumor-related death. " 11/25/2015 - "When tested against the normal cells (NIH/3T3), caseagrewifolin B (2) exhibited a significant selective inhibition against cancer cells in comparison with the normal cells. " 03/27/2015 - "Companeramides A (1) and B (2) showed high nanomolar in vitro antiplasmodial activity but were not overtly cytotoxic to four human cancer cell lines at the doses tested." 08/22/2014 - "Trichormamide B (2) was cytotoxic against MDA-MB-435 and HT-29 cancer cell lines with IC50 values of 0.8 and 1.5 μM, respectively."
4.	Stroke (Strokes) 01/01/2011 - "The results presented here will serve as priors for the design of further studies to test the efficacy of the concept with stroke patients, and the found effects will provide a basis for the development of a classifier for a future B(2)RI." 10/01/2006 - "The aim of the current study was therefore to investigate the effect of delayed B(2) receptor inhibition on morphological and functional outcome following experimental stroke. " 04/01/2014 - "In group A 6 (3.5%) patients developed stroke where as in group-B 2 (1.5%) patients developed stroke out of these 6 patients there were 2 mortalities after stroke in group-A while in group-B there was no mortality after stroke within 30 days postoperatively. " 02/01/2010 - "The patterns and densities of PAR(2) and B(2) immunoreactivity in frozen MCA sections were not altered with stroke. " 10/01/2006 - "Our data therefore suggest that inhibition of kinin B(2) receptors represents a treatment strategy for ischemic stroke which may warrant clinical validation."
5.	Inflammation 01/01/2013 - "Our results suggest that, in the absence of B(2)R, both B(1)R and AT(2)R play important compensatory roles in preventing deterioration of cardiac function and remodelling post-MI possibly via suppression of inflammation, TGFβ(1) and ERK1/2 signalling." 05/01/2010 - "Treatment with a selective B(2)R agonist initiated at the time of induction of acute MI in mice had a beneficial effect on cardiac function, tissue remodeling, and inflammation-related tissue gene expression, which may explain its structural and functional benefits." 07/01/2003 - "The components of the kinin system, including kinongens, kininogenases, and B(2) and B(1) receptors, are expressed and activated during inflammation. " 05/01/2002 - "BK B(2) receptor antagonists may prove useful for the treatment of pathological situations caused by excessively increased local kinin concentrations, such as inflammation, tissue injury and pain. " 01/01/2013 - "Blockade of AT(2)R or B(1)R worsened cardiac remodelling, hypertrophy and dysfunction associated with increased inflammation and ERK1/2 phosphorylation and decreased NO excretion in B(2)R(-/-) mice, which were exacerbated by dual blockade of B(1)R and AT(2)R. "

Related Drugs and Biologics

1.	Bradykinin
2.	icatibant
3.	LF 16-0687
4.	Glucose (Dextrose)
5.	Eicosanoids
6.	Carbon Monoxide
7.	(4- amino- 5- (4- (4- (2,4- dichloro- 3- (2,4- dimethyl- 8- quinolyloxymethyl)phenylsulfonamido)tetrahydro- 2H- 4- pyranoylcarbonyl)piperazino)- 5- oxopentyl)(trimethyl)ammonium
8.	Ammonium Chloride (Sal Ammoniac)
9.	Iodoacetates (Iodoacetate)
10.	Proteins (Proteins, Gene)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Lung Transplantation
3.	Transplants (Transplant)
4.	Nephrectomy
5.	Catheters